Understanding the etiology and pathogenesis schizophrenia and depression is a major challenge facing psychiatry. One hypothesis is that these disorders are secondary to a malfunction of neurotrophic factors. Inappropriate neurotrophic support during brain development could lead to structural disorganisation in which neuronal networks are established in a nonoptimal manner. Inadequate neurotrophic support in adult individuals could ultimately be an underlying mechanism leading to decreased capacity of brain to adaptive changes and increased vulnerability to neurotoxic damage. Brain-derived neurotrophic factor (BDNF) is a mediator involved in neuronal survival and plasticity of dopaminergic, cholinergic, and serotonergic neurons in the central nervous system (CNS). In this review, we summarize findings regarding altered BDNF in schizophrenia and depression and animal models, as well as the effects of antipsychotic and antidepressive treatments on the expression of BDNF. Molecular Psychiatry (2005) 10, 345-352.
Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) are derived from a common ancestral gene, and are collectively called neurotrophins. 1, 2 Neurotrophins have an important role in regulating development and maintenance of the peripheral (PNS) and central (CNS) nervous systems' function. Neurodevelopmental studies suggest that a combination of genetic and environmental factors is required for the manifestation of some psychiatric disorders. For instance, altered synthesis and/or release of neurotrophins during defined developmental periods could affect how neuronal networks are formed or maintained, and thus could possibly be an underlying cause for the development of disease 3 ( Figure 1 ). Moreover, antipsychotic and antidepressive treatments both regulate levels of trophic factors in the brain. Thus, regulation of neurotrophic factors could be a crucial factor in psychiatric treatments ( Figure 1 ). In this review, we analyze the findings in humans and animal models regarding the role of BDNF, the most widely distributed neurotrophin in the CNS, in the pathophysiology of schizophrenia and depression (see Figure 1 and Tables 1-2) .
BDNF gives trophic support to a variety of CNS neurons
BDNF has survival-promoting actions on a variety of CNS neurons including hippocampal and cortical neurons, 26, 27 cholinergic, 28 nigral dopaminergic, 29 and 5-HT neurons. 30 Thus, within the hippocampus, neurons from the BDNF knockout mice exhibited enhanced cell death compared with cells from the wild-type animals. 27 Moreover, exogenous BDNF increased the survival of the hippocampal neurons lacking BDNF. 27 BDNF prevents the spontaneous death of dopaminergic neurons in rat primary mesencephalic cultures 31, 32 and protects TH-immunoreactive neurons from the selective toxin MPP þ (1-methyl-4-phenylpyridinium). 29 Repeated intrastriatal injections of BDNF protect from damage induced by intrastriatal administration of 6-OHDA, 33 with moderate preserving of striatal dopaminergic nerve endings around the injection site. Likewise, direct nigral infusion of BDNF protects against reductions in striatal dopamine content induced by neurotoxins in the mouse. 34 BDNF exerts a potent neurotrophic effect on the 5-HT neurons when infused into midbrain, 35 while infusion of BDNF into forebrain results in a dramatic elevation of 5-HT neuronal fiber density and protection of neurons from neurotoxic damage. 36 In addition, BDNF expression can also be regulated by serotonin. 17, 37, 38 Finally, BDNF promotes survival of rat embryonic septal cholinergic neurons in vitro and increases the activity of enzymes involved in choline acetyl transferase synthesis and degradation. 28 It should be mentioned, however, that BDNF is not as effective as the related and structurally similar NGF in both protection and recovery of the forebrain cholinergic neurons. 39, 40 Recent findings demonstrated that BDNF is anterogradely transported in the CNS, a fact that considerably expands the concept of neuronal-derived trophic support and offers some support for the hypothesis that BDNF, in similarity to neurotransmitters, can act at the synaptic level, 41 and might thus have a broader function than assumed previously. Also, numerous central neurons coexpress BDNF and its receptor TrkB. 42 Thus, BDNF has the potential to function via different mechanisms such as: (1) a neurotransmitter-like axodendritic communication, (2) in autocrine loops and paracrine interactions between neighboring cells; and (3) in trophic mechanisms, as retrograde communication from axon terminals to the cell body.
The multitude of BDNF actions on different types of neurons has supported the view that malfunctioning of this neurotrophin may be a contributing factor in the development of psychiatric disorders, while effects of antipsychotic and antidepressive treatments on BDNF and its receptor will lead to long-term adaptive changes in brain function (Figure 1 ).
BDNF and schizophrenia
The etiology and pathophysiology of schizophrenia have not been elucidated and it is conceivable that a variety of CNS changes can lead to the clinical manifestation of the disease. Studies on post-mortem Reduction of TrkB and BDNF-positive neurons in CNS 5 and BDNF in the serum 6 of schizophrenics Polymorphisms of BDNF gene associated with schizophrenia [7] [8] [9] Animal models Reduced BDNF mRNA in the prefrontal cortex and hippocampus in animals with neonatal ibotenic acid lesions of the ventral hippocampus 10, 11 Administration of the NNMDA receptor antagonist MK-801 reduces the hippocampal expression of BDNF 12 Rats prenatally exposed to antiproliferative agent MAM show behavioral deficits associated with significant decreases in BDNF in the hippocampus 13 Mice with knockout of the trkB receptor present behavioral symptoms similar to those of mouse models of schizophrenic-like disorder 14 Table 2 Summary of the main findings supporting the hypothesis of BDNF involvement in depression in humans and animal models
Human
Decreased plasma levels of BDNF in patients with major depression 15 Increased BDNF immunoreactivity in the hippocampus of post-mortem tissue from patients treated with antidepressant drugs 16 
Animal models
Chronic administration of antidepressants increases BDNF expression in the hippocampus 17, 18 BDNF has antidepressant-like activity in learned helplessness paradigms and the forced swim test 19 Environmental stressors decrease central BDNF mRNA 8 Higher BDNF levels in the frontal cortex, occipital cortex, and hypothalamus of the 'depressed' FSL animals relative to the FRL controls 20 Decreased central BDNF in models of stress-induced depression 17, 21, 22 Downregulation of the Trk-B signaling pathway in the genetic animal models of depression 23 ECS, used as an ECT model, increases BDNF in the hippocampus, striatum, and occipital cortex 24 Lithium increases the expression of BDNF in the hippocampus and cortex of rats 25 BDNF in schizophrenia and depression F Angelucci et al tissue from schizophrenic subjects and MRI data in vivo suggest ongoing specific neurodegeneration. 43 There is also strong evidence suggesting that nonheritable factors in the pathogenesis of schizophrenia are associated with abnormalities during prenatal development. Indeed, epidemiological data show increased incidence of schizophrenia in humans prenatally exposed to virus, 44 gestational complications or malnutrition. 45, 46 In addition, postmortem studies have indicated that certain limbic or associative brain areas of schizophrenic subjects have decreased cell numbers and volume, 47, 48 disorganized cytoarchitecture, and reduced content of certain microtubule-associated proteins. 49 These findings have suggested a failure of both setting and migration of young neurons into their appropriate cortical target sites, particularly in the hippocampus and entorhinal cortex. 50, 51 Neurotrophins play key roles in growth and differentiation during development as well as in plasticity and survival of adult hippocampal and cortical structures. Thus, the neurotrophin hypothesis of schizophrenia 52 has postulated that the changes in the brain of schizophrenic patients is the result of disturbances of developing processes involving these molecules. Neurotransmitter deficits are thereby considered as epiphenomena of underlying neurotrophin disorganization. This hypothesis is supported by studies showing that NGF and BDNF are abnormally regulated in the CNS of animal models of schizophrenia, [53] [54] [55] [56] 13, 57 and by the findings that schizophrenic patients have reduced number of TrkB and BDNF-positive neurons 5 and BDNF in the serum. 6 Results from studies on human post-mortem tissues from schizophrenic patients show a significant decrease in BDNF concentrations in cortical areas and the hippocampus, 4 whereas other authors have reported that BDNF protein is elevated in the anterior cingulated cortex and hippocampus of schizophrenics. 58 These data were taken as further evidence for the hypothesis that alterations in the expression of neurotrophins participate in the neural maldevelopment and the disturbed neural plasticity in schizophrenic patients. A genetic link between neurotrophins and schizophrenia is supported by the evidence that polymorphisms of the NT-3 and BDNF genes are associated with schizophrenia. [7] [8] [9] Lastly, findings that BDNF is decreased by factors correlated with first episode onset, such as stress 59, 21 and estrogen withdrawal, 60 are also consistent with the putative BDNF role in schizophrenia. Interestingly, these stress-induced decreases in BDNF are blocked by 5-HT2 receptor antagonists, a receptor binding property of many neuroleptics. 37 Electroconvulsive treatment (ECT), effective in treatment-resistant schizophrenia in combination with neuroleptics, 61 also upregulates the expression of BDNF. 62, 18 For these reasons, in addition to providing a link between neurodevelopmental and neurodegenerative phenomena, BDNF is an attractive candidate target molecule in the treatment of schizophrenia.
BDNF and animal models of schizophrenia
A wealth of experiments, in humans administering compounds that produce/exacerbate symptoms of schizophrenia, and in animals using lesion models, have been carried out. [63] [64] [65] [66] For example, neonatal damage of the ventral hippocampus or amygdala, [67] [68] [69] administration of amphetamine 70 inducing disruption (and probably blocking) of latent inhibition, or phencyclidine 71 inducing changes in the startle response provided productive animal models with construct, face, and predictive validity for schizophrenia. It has been shown 72, 73 that interference with neurogenesis in the mediotemporal allocortex of rat embryos, during the earliest stages of cortical proliferation, results not only in a thickness reduction of the adult entorhinal cortex and hippocampus 55, 73 but also in other morphological characteristics resembling those observed in patients with schizophrenia. 50 A model displaying these structural brain deficits was obtained administering a single injection of methylazoxymethanol acetate (MAM) in pregnant rats 74 on gestational day 11 or 12 when the entorhinalhippocampal axis is in the major cell proliferation phase. 75 Results from these animal models have supported the hypothesis that BDNF plays a role in the pathophysiology of schizophrenia. For example, animals with neonatal ibotenic acid lesions of the ventral hippocampus show decreased BDNF mRNA levels in the prefrontal cortex and hippocampus. 10, 11 Administration of the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 reduces the hippocampal expression of BDNF. 12 Young rats exposed to MAM on gestational day 12 showed deficits in both the acquisition and retention phases of the Morris maze, and these changes were associated with significant decreases in NGF and BDNF in the hippocampus. 13 A link between administration of antipsychotic drugs in rats and tissue levels of BDNF has been reported. 76, 77 We found that administration of antipsychotic drugs, such as haloperidol and risperidone, decreased levels of BDNF in the frontal and occipital cortex and hippocampus, whereas only haloperidol, which mainly acts on the dopamine(DA)-D 2 and D 3 receptors, significantly reduced the number of TrkBimmunoreactive neurons in the hippocampus, substantia nigra and ventral tegmental area. 78 These studies support the hypothesis that antipsychotic drugs exert their effect, at least in part, by modifying the synthesis and distribution of BDNF in selected brain regions.
Another model is genetic, that is, mice with a forebrain-specific knockout of the trkB receptor. The behavioral profile of these trkB-mutant mice comprises hyperlocomotion, stereotyped behaviors, and cognitive impairments, similar to those postulated for mouse models of schizophrenic-like disorder.
14 A summary of reported data involving BDNF in schizophrenics and in animal models is presented in Table 1 .
BDNF and depression
A number of findings suggest that BDNF action could be impaired in depression and stress-related affective disorders, and that BDNF is involved in the etiology of these illnesses. Duman and co-workers 17 first demonstrated that chronic administration of several antidepressants, including selective serotonin reuptake inhibitors, increases BDNF expression in the hippocampus. Another study demonstrated that centrally administered BDNF produces antidepressant-like activity in learned helplessness paradigms and the forced swim test. 19 Therefore, upregulation of BDNF in response to antidepressant treatment could have similar behavioral effects. This is further supported by an animal study demonstrating that environmental stressors, such as immobilization, decreased central BDNF mRNA. 8 Indeed, chronic stress downregulates neurotrophin synthesis causing atrophy and, in severe cases, death of vulnerable CA3 neurons in the hippocampus. 79 Stress also decreases the expression of BDNF in CA3 pyramidal and dentate gyrus granule cell layers of the hippocampus. 59, 80 These observations led to the hypothesis that downregulation of BDNF could contribute to accelerate the atrophy of CA3 neurons, making these neurons more susceptible to other factors, such as adrenal glucocorticoids that are induced in response to repeated stress. Brain imaging studies have reported a small but significant reduction in the volume of hippocampus in patients with depression or post-traumatic stress disorder. [81] [82] [83] Atrophy and decreased functions of the hippocampus could explain the reduction, observed in depressed patients, in negative feedback control that this brain region exerts on the hypothalamic-pituitary-adrenal axis. 84 Other studies have shown decreased plasma levels of BDNF in patients with major depression 15 and increased BDNF level in hippocampus in postmortem tissue from patients treated with antidepressant drugs. 16 In addition, the prefrontal cortex has been postulated to have a role in the neuropathology in depression. 85 On the other hand, there is a paucity of genetic studies on depression and neurotrophins, 86, 87 and they are essentially negative. Thus, involvement of BDNF in depression requires further studies.
BDNF and animal models of depression
To date, a wide range of animal models of depression has been developed. They include models in which 'depressive behavior' is the result of genetic selection or manipulation, environmental stressors during development or in adulthood, or pharmacological treatments. Genetic models of depression include the Fawn-Hooded (FH) rat, an inbred rat strain with high immobility in the forced swim test, 88 and the Wistar Kyoto (WKY) rat, characterized by hyper-reactivity to stress and depressive-like behavior in several standard behavioral tests. 89 The Flinders sensitive line (FSL) rats and their corresponding controls, the Flinders resistant line (FRL) rats, were established by selective breeding for high and low sensitivity, respectively, to the anticholinesterase agent, diispopropyl fluorophosphate. 90 This rat line was originally developed based on the fact that an overactive cholinergic system seems to be associated with depression-like behavior, 91 and some data support the claim that patients with affective disorder display increased sensitivity to cholinergic agonists. 92, 93 Early maternal separation that induces a response characterized by reduced activity and other depressiverelated behaviors in adult life has also been used. 94 Anhedonia, assessed in rats with, for example, sucrose consumption test, induced by a regimen of repeated, mild, unpredictable stressors, is also supposed to be a model of depression with predictive and etiological reliability. 95 It is conceivable that in pathophysiology of depression as well as in mechanisms of its treatment, BDNF plays a role also in other brain regions than the hippocampus and cerebral cortex. For instance, in depression, the subjects suffer from anhedonia that is characterized by the lack of motivation to engage in behaviors that will generate reward or well-being. The mesolimbic dopaminergic ventral tegmental area-nucleus accumbens pathways is critical for motivation and reward. BDNF and TrkB are expressed in these pathways and it is possible that a disturbance in BDNF function in mesolimbic reward pathways could be an underlying neurobiological mechanism for the anhedonia component of depression. 96, 97 In addition, learned helplessness, in which exposure to inescapable stress produces deficits in escape, has been proposed as an animal model of stress-induced behavioral depression. 98 To better characterize these models, a variety of pharmacological treatments has been tested. The reliability of these animal models is based on both behavioral tests measuring traits that are homologous to symptoms of the human disorder and behavioral tests responsive to appropriate pharmacologic treatments.
We have recently shown in the FSL/FRL genetic model of depression, higher BDNF levels in the frontal cortex, occipital cortex, and hypothalamus of the FSL animals relative to the FRL controls. 20 However, there were no differences in baseline BDNF mRNA levels comparing two other strains of rats, one bred for helplessness in response to stress (cLH) and the other based on selection for resistance (cNLH). 99 These results are not consistent with the findings of other researchers using models of stress-induced depression, 17, 21, 22 where decreased central BDNF was demonstrated. Unchanged or increased BDNF levels in animal models of depression compared to controls would seem to be at variance with the assumed decreased CNS BDNF in human depression. Several processes could account for such discrepancies, for example, increased baseline BDNF reflects a compensatory increase in its synthesis occurring in response to downregulation of the Trk-B signaling pathway in the genetic animal models of depression, as suggested by Tsay, 23 or increased level of BDNF could reflect a lower turnover rate of BDNF with a higher pool of BDNF in the tissue that is not released.
Data on antidepressive treatments such as ECT and lithium obtained in animal models point to a possible role of BDNF in the treatment of depression. We demonstrated in Sprague-Dawley rats that repeated electroconvulsive stimuli (ECS), used as an ECT model, increased the concentrations of BDNF in the hippocampus, striatum, and occipital cortex. 24 Lithium, probably the most effective mood stabilizer, has been shown to induce an increase in the expression of BDNF in the hippocampus and cortex of rats. 25 While the increase in hippocampus BDNF is present after 14 and 28 days treatment, the increased levels in the frontal cortex are attenuated after 28 days. Effect of chronic lithium treatment on brain BDNF was also investigated in the 'depressed' FSL rats and their controls, the FRL line; significantly altered constitutive brain concentrations of BDNF were found. 100 In contrast to the work cited above that used a 7-, 14-or 28-day lithium treatment period, 25 we did not see changed BDNF levels in the hippocampus in any of the rat strains after 42 days of lithium. We also did not observe the reported increased BDNF levels in the frontal cortex. Significantly, in the above study the effect was strong at 14 days but gone after 28 days of treatment. In our study, we administered lithium for 42 days, and found that in depressed FSL rats, the levels of BDNF were decreased after this much longer treatment. This apparent discrepancy could be due to the fact that different durations of lithium treatments were used in the two studies and, moreover, that the lithium effects on BDNF regulation in the frontal cortex depends on whether the animal is depressed or not.
Since lithium is efficient in treatment and prophylaxis of both phases of bipolar disorder, 101 it could be speculated that the manic state is associated with malfunctioning of BDNF activity and one mechanism of lithium's action would be to normalize this. Interestingly, atypical antipsychotics have been used for the treatment of both mania 102 and depression; 103 clozapine and risperidone decreased BDNF in the hippocampus, 35, 11 while another atypical antipsychotic, quetiapine, attenuates immobilization stress-induced decrease in BDNF expression in the rat hippocampus. 104 It is possible, therefore, that lithium may exert a stabilizing effect on BDNF function. In view of the absence of an adequate animal model of bipolar disease as well as no BDNF data in the manic phase of the bipolar disease, these speculations cannot be currently verified.
A summary of data reported involving BDNF in human depression and in animal models is presented in Table 2 .
Summary
Neurodevelopmental abnormalities, genetic or environmental, may result in increased predisposition to schizophrenia. 43 The maldevelopment hypothesis postulates abnormal structural development and maturation of certain brain areas, including disturbances of cell migration, disconnections, and changes in neural plasticity, as important factors in the pathogenetic cascade of schizophrenia. Experiments using animal models indicate that neurotrophins, particularly BDNF, play a role in neurodevelopmental disorders. 54, 58, [105] [106] [107] Human studies showing altered BDNF levels in schizophrenic patients, both in plasma and the CNS, 54, 58 suggest that changes in the expression of BDNF might contribute to the disease pathophysiology, one aspect of which is a disturbed capacity for functional plasticity in these individuals.
With regard to depression, data from humans and animal models indicate that depression may be associated with the inability of neuronal systems to exhibit appropriate adaptive plasticity. 49, [108] [109] [110] [111] [112] [113] [114] [115] [116] Recent basic and clinical studies provide evidence for a 'neurotrophin hypothesis' of depression and antidepressive treatments. 111, 117, [113] [114] [115] [116] This concept postulates that plasticity-related changes, like hippocampal atrophy in depressed patients, are related to a decreased expression or function of BDNF and/or its high-affinity receptor TrkB. 111, 117, [114] [115] [116] 118 These results, together with the antidepressive effects of BDNF in mouse models of depression, 119 and the increased BDNF levels in patients treated with antidepressants, 16 suggest a central role for this neurotrophin and its receptor in the molecular mechanisms of antidepressive therapy.
